Health & Sciences

What Jim Tananbaum, A Seasoned Investor In Healthcare Thinks About The Future Of Medicine

Quality healthcare is one of the pillars of modern civilization. Without proper healthcare human face the threat of extinction. A lot of research goes into ensuring that vaccines and effective therapies are designed. Millions of dollars are committed by governments, individuals and private organizations to research and drug development. It is true that for the war against some of the humanity’s intractable diseases to be won, various stakeholders have to come together and invent solutions.

One of the business leaders who has taken a bold step in the fight against diseases is Jim Tananbaum. Jim is the brainchild of Foresite Capital. He also doubles as the Chief Executive Officer of the enterprise. Foresite Capital is the company which focuses on providing solutions in the healthcare sector. The company is privately held and is keen on identifying emerging trends and leaders in the medical industry. Once the company has identified a leader or solution in healthcare, it chips in and helps to nurture the leaders through the provision of capital, networks, and data that can contribute to the growth of solutions in medicine. You can visit LinkedIn for more info.

At the moment, one of Foresite’s most important investments is Intarcia. Intarcia is a diabetes implant that is administered to people living with diabetes twice a year, and it enables them to control their sugar levels efficiently and also cut weight. This product helps a lot of individuals to lead a normal life and carry out their daily activities with the ease of a healthy person. Intarcia is expected to make a debut in the United States medical market at the end of the year 2017. Check out LinkedIn Forsite Capital.

Before we knew Jim with his company Foresite Capital, the entrepreneur had already made it big in the bio-pharmaceutical market. He co-founded two leading bio-pharmaceutical companies namely GelTex Pharmaceuticals and NASDAQ: GENZ. These companies pioneered two drugs at a modest budget of $80 million.

Jim has achieved a lot in the field of pharmaceuticals. Some of the most important investments he has made include Prospect Venture Partners II and III and Sierra Ventures. Tananbaum is also a seasoned academician with an M.D and M.B.A from Harvard and an M.S. from MIT. More details can be found on Crunchbase.

Visit his Facebook page.

 

Posted by on .